ASH 2021 Ambassador Program and Novartis MPN / GvHD content

Go back to homepage ⟶

ASH 2021 MPN key presentations

The SWITCH study is a multinational, retrospective chart review study is to assess the event-free survival rate of high-risk patients with PV who receive ruxolitinib as 2L therapy (switchers) vs those who continue receiving 1L therapy (non-switchers) after suboptimal response

Access here

The ADORE study is a three-part, open-label, multicenter, phase 1/2 platform study assessing the safety and efficacy of RUX in combination with five novel compounds that impact the hematopoietic environment through different mechanisms

Access here

ASH 2021 Ambassador Program*

Canadian experts from across the country came together to curate the latest data from ASH 2021, with a focus on how the data may impact clinical practice.

Coming soon

* The content for this program was independently developed by the program steering committee, who are solely responsible for this content, including any information on unapproved use(s) of a product. Novartis Pharmaceuticals Canada Inc. has provided only financial and/or logistical support for this educational activity.

Des experts canadiens se sont réunis pour analyser les dernières données de ASH 2021, en mettant l'accent sur la façon dont ces données peuvent avoir un impact sur la pratique clinique.

Bientôt disponible

* Le contenu de ce programme a été développé de manière indépendante par un comité directeur de professionnels de la santé qui est seul responsable de ce contenu, y compris toute(s) information(s) sur l'utilisation non approuvée d'un produit.
Novartis Pharmaceuticals Canada Inc. n'a fourni qu'un soutien financier et/ou logistique pour cette activité éducative.

177908 - 177910
×

Medical Information Request

×

Ask Speakers